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GUEST EDITORIAL
Monitoring cancer trends
F. Blyth & V. Beral
ICRF, Cancer Epidemiology Unit, University ofOxford, Gibson Building, The Radcliffe Infirmary, Oxford OX2 6HE, UK.
The article by Hill et al. in this issue of the British Journal of
Cancer p. 587-590 describes cancer mortality in France from
1950 to 1985 among men and women aged 35 to 64 years.
The authors conclude that the occurrence of cancer and
trends over time in France are generally similar to those
described in other Western countries, except that oral,
pharyngeal and oesophageal cancers are especially common
in France and lung cancer is relatively uncommon. The main
increases in mortality since the 1950s at ages 35 to 64 years
have been for the cancers whose risk is enhanced by tobacco
smoking or by alcohol consumption - cancers of the lung,
oesophagus, pharynx, tongue and mouth.
Hills et al.'s paper is one of several recent commentaries on
cancer trends (Davis et al., 1990; Doll, 1990). Davis et al.
(1990) conclude that there is an increase in cancer mortality
which is 'so great and rapid that their causes demand inten-
sive investigation', whereas Doll (1990) asks 'are we winning
the fight against cancer?' and concludes that we may be. How
could the authors reach such apparently different conclu-
sions?
Davis et al.'s (1990) concern that cancer is increasing
rapidly is based on analyses of mortality from selected
cancers in men and women at ages 55 years and above in six
countries, including France and England and Wales. Cancers
of the lung and stomach were excluded from their analyses.
These omissions alter the overall trends substantially. In
England and Wales, for example, malignancies of the lung
and stomach together account for half the cancer deaths in
men and a quarter of the cancer deaths in women; and some
of the most spectacular reductions in mortality have occurred
for these two conditions. Lung cancer mortality rates rose
dramatically during the 1950s and 60s, but are now declining
in men at all ages under 85 years, and in women at all ages
under 60 years (OPCS). These trends are largely the conse-
quence of changes in cigarette smoking, perhaps with an
added contribution from reduced levels of air pollution.
Stomach cancer mortality rates have been declining in Eng-
land and Wales and all Western countries throughout this
century. The increasing consumption of fresh fruit and vege-
tables, which have been associated with a lowered risk of
stomach cancer, may account for at least part of the decline.
After excluding lung and stomach cancers, the trends in
the remaining cancers which Davis et al. (1990) describe are
dominated by breast cancer in women and prostatic cancer in
men. Mortality rates from breast and from prostatic cancer
are known to be increasing at ages 55 years and older in
England and Wales and in most of the countries included in
their analyses. Of the other cancers which are common at
ages 55 and over, mortality attributed to some, such as
colo-rectal and oesophageal cancer is declining whereas
mortality attributed to others, namely bladder cancer, non-
Hodgkin's lymphoma, multiple myeloma, and brain cancer is
increasing. More accurate diagnosis of cancer in the elderly,
rather than a true increase in cancer incidence may account
for the increases in mortality ascribed to some cancers such
as multiple myeloma and brain cancer. Thus there is no
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unknown or unexpected increase in cancer in the elderly -
Davis et al.'s analysis has highlighted the known increases in
breast and prostatic cancer in an unusual way. Despite inten-
sive research into the causes of these two cancers there is still
no widely accepted reason for why they are increasing.
Animal fats have been implicated as possible causes of both
types of cancer and the most favoured explanation for the
trends is that they are the result of the dietary changes which
have occurred in Western countries throughout this century.
One of the major issues which epidemiologists are now tackl-
ing is the relation of diet to cancer - not only for breast and
prostatic cancer, but also for gastric, colonic and pancreatic
cancer. There may soon be sufficient evidence to permit firm
conclusions to be drawn about the role of dietary factors in
these cancers. This should aid our interpretation of the
trends, as well as suggesting appropriate preventive measures.
Not only are diagnostic artefacts a problem in the elderly,
but the time between exposure to a carcinogen and the onset
of cancer is likely to be long in old people. A cancer which
occurs today in an elderly person is often the consequence of
an exposure which took place many decades ago, whereas a
cancer in a young person could not be due to an exposure to
a carcinogen which occurred too many decades ago. Doll
(1990) argues that if we wish to evaluate the effects of
changes in recent exposures to carcinogens we should con-
centrate on cancer trends in young people. He shows that
mortality from all cancers combined is declining in men and
in women under the age of 45 years in England and Wales
and in many Western European countries (but not in Eastern
Europe). In England and Wales this is the result of a decline
in mortality from most of the common cancers - of the
stomach, colon, rectum, lung, larynx, ovary, testis, bladder
and thyroid and of leukaemia and Hodgkin's disease. The
only common cancers not now showing a decline in mortality
are breast and prostate cancer, and mortality rates for these
two cancers are increasing fairly slowly. The few cancers
which show substantial increases in mortality are some of the
rare ones - liver cancer, malignant melanoma, cervical
cancer, connective tissue malignancies, non-Hodgkin's lym-
phoma and mesothelioma. The likely reasons for the inc-
reases in these cancers are discussed by Doll (1990), but the
most important conclusion is that the overall trends at ages
45 and younger are downwards.
Is the decline in mortality from many of the common
cancers in young people in England and Wales and in many
European countries due to improved survival, a falling
incidence or both? For cancers with a poor prognosis, such
as stomach and lung cancer, the falling mortality rates un-
doubtably follow a decline in incidence. For cancers where
substantial therapeutic successes have been achieved, such as
childhood lymphoid leukaemia, Hodgkin's disease and testi-
cular cancer, improved survival has contributed to the declin-
ing mortality. But for other cancers, especially cancer of the
colon, rectum, and ovary, the reasons for the downward
trend in mortality is not obvious. It is clearly important to
know whether their incidence is declining or whether survival
is improving. A decline in incidence would reflect changing
exposures to carcinogens or perhaps successful interventions
from cancer prevention programmes, whereas improvements
in survival would reflect earlier diagnosis and/ or improved
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treatment. To answer these questions it is necessary to look
beyond mortality data and to turn to cancer incidence and
survival statistics.
Cancer incidence and survival data in England and Wales
are collected by 12 regional cancer registries. Cancer registra-
tion is voluntary, the coverage of the population is not
always complete and thus cancer registration rates may not
be a reliable measure of incidence (Swerdlow, 1986).
Accurate national survival statistics are even more difficult to
obtain than are incidence data as the continued follow-up of
patients with cancer is required for the estimation. Intuitively
it might be expected that the difference between the number
of people developing a cancer and the number who die from
cancer are the survivors. Leaving aside problems of obtaining
reliable incidence data, the relationship is not so simple.
Deaths from the cancer may occur many years after diag-
nosis and other illnesses may intervene.
There are examples in the cancer statistics for England and
Wales where the respective registration, survival and mortal-
ity trends do not seem to make sense. For example, breast
cancer registration rates are increasing considerably more
rapidly than are the mortality rates. The increase in breast
cancer registration rates cannot be entirely due to more
complete coverage of the population since registration of
other cancers is not increasing so rapidly. Are the discrepant
trends due to improvements in survival? Newly introduced
treatments for breast cancer could at best result in only
modest improvements in survival (Early Breast Cancer Trial-
ists' Collaborative Group, 1990) so this seems an unlikely
explanation. It is possible that women with breast cancer are
presenting earlier than they did in the past. But it is also
possible that there is an increasing tendency to label tumours
which are biologically benign as malignant. As screening
programs become more widespread borderline lesions which
would otherwise never have come to light may be increasing-
ly identified and labelled as malignant. The labelling of such
lesions as malignant would falsely inflate estimates of cancer
incidence and result in artefactual improvements in survival.
The Nordic countries lead the world in the quality and
completeness of their cancer registries. Their results suggest
that much can be learnt from reliable cancer registration and
survival statistics. Adami and colleagues (1989) examined
Swedish Cancer Registry Data from 1960 to 1984 and noted
that major improvements in survival had occurred over the
25 year period. They concluded that the survival patterns
were indicative of patients presenting earlier for treatment
and of true improvements in therapy and were not biased by
the methods of data collection or follow-up or by the in-
clusion of borderline lesions which were clinically benign. In
England and Wales cancer incidence and survival statistics
are not as complete or reliable as in the Nordic countries and
the main source of the errors and their magnitude is un-
known and unstudied.
When mortality rates are declining it is clearly important
to know whether this is the result of changes in survival,
cancer incidence or both. In the past, declining mortality
rates could be interpreted simply, since cancer survival was
usually dismal and did not change much over time, so mor-
tality trends reflected incidence reasonably well. Nowadays
the relation between cancer incidence, survival and mortality
is not so straightforward. The development of effective thera-
pies may well be lengthening survival for some patients and
resulting in permanent cure for others. Furthermore dietary
changes are occurring and exposures to carcinogens are alter-
ing, and these may well be altering cancer incidence rates.
There are already promising trends in England and Wales
and in many Western European countries, in that mortality
from the common cancers is declining in young people.
Generations which experience a low mortality from cancer at
young ages tend to maintain that low mortality throughout
life, so it is not unreasonable to expect that the substantial
decline in mortality which is now evident in young adults will
extend to older ages in the future. The challenge to resear-
chers of the future may well be to explain why cancer mor-
tality is declining. Disentangling the effects of changes in
cancer survival and incidence would then be a key issue. The
Working Group which reviewed the National Cancer Regist-
ration Scheme (Office of Population Censuses and Surveys,
1990) drew attention to the lack of support for registries and
recommended that the existing scheme be improved and
adequately funded. Cancer registries need to be safeguarded
so that we can continue to monitor cancer trends in the
future.
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